{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:13:24Z","timestamp":1788394404484,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"abstract":"<jats:p>The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who received either cefoperazone-sulbactam or piperacillin-tazobactam in the treatment of SCAP. A total of 815 SCAP patients were enrolled. Among them, 343 received cefoperazone-sulbactam, and 472 received piperacillin-tazobactam. Patients who received cefoperazone-sulbactam presented with higher Charlson Comorbidity Index scores. (6.20\u2009\u00b1\u20092.77 vs 5.72\u2009\u00b1\u20092.61; <jats:italic toggle=\"yes\">P<\/jats:italic> = .009). The clinical cure rates and effectiveness for patients receiving cefoperazone-sulbactam and piperacillin-tazobactam were 84.2% versus 80.3% (<jats:italic toggle=\"yes\">P<\/jats:italic> = .367) and 85.4% versus 83.3% (<jats:italic toggle=\"yes\">P<\/jats:italic> = .258), respectively. In addition, the overall mortality rate of the cefoperazone-sulbactam group was 16% (n = 55), which was also comparable to the piperacillin-tazobactam group (17.8%, n = 84, <jats:italic toggle=\"yes\">P<\/jats:italic> = .572). The primary clinical outcomes for patients receiving cefoperazone-sulbactam were superior compared to those receiving piperacillin-tazobactam after adjusting disease severity status. The clinical efficacy of cefoperazone-sulbactam in the treatment of adult patients with SCAP is comparable to that of piperacillin-tazobactam. After adjusting for disease severity, cefoperazone-sulbactam tended to be superior to piperacillin-tazobactam.<\/jats:p>","DOI":"10.1097\/md.0000000000034284","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T16:22:00Z","timestamp":1689697320000},"page":"e34284","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia"],"prefix":"10.1097","volume":"102","author":[{"given":"Chih-Cheng","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Kuo","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Tung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Kuei","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chi","family":"Ku","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yen","family":"Tu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-6000","authenticated-orcid":false,"given":"Wen-Chien","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QCO.0000000000000349","article-title":"Severe community-acquired pneumonia: optimal management.","volume":"30","author":"Leoni","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13054-016-1414-2","article-title":"Severe community-acquired pneumonia: timely management measures in the first 24 hours.","volume":"20","author":"Phua","year":"2016","journal-title":"Crit Care"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e0145929","DOI":"10.1371\/journal.pone.0145929","article-title":"Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia.","volume":"11","author":"Montull","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e0191721","DOI":"10.1371\/journal.pone.0191721","article-title":"Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients.","volume":"13","author":"Ferrer","year":"2018","journal-title":"PLoS One"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1702215","DOI":"10.1183\/13993003.02215-2017","article-title":"Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.","volume":"51","author":"Cilloniz","year":"2018","journal-title":"Eur Respir J"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc13812","article-title":"Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort.","volume":"18","author":"Walden","year":"2014","journal-title":"Crit Care"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.medin.2015.07.005","article-title":"Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia.","volume":"40","author":"Valles","year":"2016","journal-title":"Med Intensiva"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0012-3692(15)50958-6","article-title":"Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia.","volume":"130","author":"Shorr","year":"2006","journal-title":"Chest"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10096-012-1802-8","article-title":"Incidence of respiratory viruses in patients with community-acquired pneumonia admitted to the intensive care unit: results from the Severe Influenza Pneumonia Surveillance (SIPS) project.","volume":"32","author":"Wiemken","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.chest.2016.03.042","article-title":"Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa.","volume":"150","author":"Cilloniz","year":"2016","journal-title":"Chest"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.","volume":"12","author":"Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/ciy631","article-title":"A therapeutic strategy for all pneumonia patients: a 3-Year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.","volume":"68","author":"Maruyama","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/microorganisms7020049","article-title":"PES pathogens in severe community-acquired pneumonia.","volume":"7","author":"Cilloniz","year":"2019","journal-title":"Microorganisms"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2019.11.006","article-title":"Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America.","volume":"91","author":"Sader","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2147\/IDR.S313828","article-title":"Clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.","volume":"14","author":"Chen","year":"2021","journal-title":"Infect Drug Resist"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e00023-19","DOI":"10.1128\/AAC.00023-19","article-title":"Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia.","volume":"63","author":"Liu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan.","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/14787210.2018.1512403","article-title":"Severe community-acquired pneumonia: current management and future therapeutic alternatives.","volume":"16","author":"Garnacho-Montero","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.","volume":"188","author":"Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"R21-20250504","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1093\/clinids\/5.Supplement_1.S108","article-title":"Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.","volume":"5","author":"Jones","year":"1983","journal-title":"Rev Infect Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jmii.2017.08.026","article-title":"The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.","volume":"51","author":"Chang","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"R23-20250504","first-page":"190","article-title":"Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.","volume":"115","author":"Moody","year":"1990","journal-title":"J Lab Clin Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12879-016-1717-6","article-title":"Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.","volume":"16","author":"Ye","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jmii.2015.08.024","article-title":"Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone-sulbactam.","volume":"50","author":"Jean","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14740338.2020.1713090","article-title":"Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e0158407","DOI":"10.1371\/journal.pone.0158407","article-title":"Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study.","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:21:17Z","timestamp":1746321677000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":28,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034284","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}